Chemo-immunotherapy: A new option for non-small cell lung cancer

Cancer Biology and Therapy

Volumn 8, Issue 6, 2009, Pages 503-504

  Vitale, Giovanni ^a,b   Abbruzzese, Alberto ^c   Tonini, Giuseppe ^d   Santini, Daniele ^d  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Chemotherapy; Immunotherapy; Non small cell lung cancer

Indexed keywords

AGATOLIMOD; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; NAVELBINE; PACLITAXEL; RECOMBINANT INTERLEUKIN 2; VIRUS VECTOR;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG WITHDRAWAL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE;

EID: 66149105874     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.6.7770     Document Type: Note

References (16)

1. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001.
2. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61. (Pubitemid 46067386)
3. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007; 14:1848-1850 (Pubitemid 47423653)
4. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-1059 (Pubitemid 47517504)
5. Levitt ML, Kassem B, Gooding WE, Miketic LM, Landreneau RJ, Ferson PF, et al. Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: Results and possible immune system related mechanisms. Lung Cancer 2004; 43:335-344 (Pubitemid 38224155)
6. Zhang L, Dermawan K, Jin M, Liu R, Zheng H, Xu L, et al. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol 2008; 129:219-229
7. Correale P, Tindara Miano S, Remondo C, Migali C, Rotundo MS, Macrì P, et al. Secondline treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. Cancer Biol Ther 2009; 8:497-502.
8. Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, et al. Dendritic cell (DC)-mediated crosspresentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil and leucovorin (GOLF) elicits a powerful human antigen-specific CTL response with anti-tumour activity in vitro. J Immunol 2005; 175:820-828 (Pubitemid 41094964)
9. Le UM, Yanasarn N, Löhr CV, Fischer KA, Cui Z. Tumor chemo-immunotherapy using gemcitabine and a synthetic dsRNA. Cancer Biol Ther 2008; 7:440-447
10. Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 2005; 54:915-925 (Pubitemid 40991334)
11. Manthey CL, Qureshi N, Stütz PL, Vogel SN. Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages. J Exp Med 1993; 178:695-702. (Pubitemid 23218219)
12. + cytotoxic T lymphocytes. Cancer Immunol Immunother 2001; 50:445-455
13. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Lévy E, et al. A Phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 2008; 3:735-744
14. Manegold C, Thatcher N, Benner RJ, Readett D, van Zandwijk N. Randomized phase III trial of gemcitabine/cisplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26.
15. Hirsh V, Boyer M, Rosell R, Benner RJ, Readett D, Schiller JH. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26.
16. Ratto GB, Cafferata MA, Scolaro T, Bruzzi P, Alloisio A, Costa R, . Phase II study of combined immunotherapy, chemotherapy and radiotherapy in the postoperative treatment of advanced non-small-cell lung cancer. J Immunother 2000; 23:161-167 (Pubitemid 30079837)